China · Health Care · CNY (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in CNY (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for 禾元生物-U (Hé Yuán Shēng Wù -u)? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -22.71% | -0.95% | -0.79% | -0.98% | -1.23% | -1.27% |
|---|---|---|---|---|---|---|
| ROA | -14.96% | -0.52% | -0.4% | -0.46% | -0.53% | -0.51% |
| Gross Margin | 63.49% | 62.55% | 61.79% | 61.37% | 59.58% | 59.41% |
| Net Margin | -600.28% | -20.23% | -15.2% | -16.83% | -19.68% | -18.19% |
| Total Assets | CN¥1,061,811.88K | CN¥1,134,927.91K | CN¥1,213,993.55K | CN¥1,299,494.80K | CN¥1,390,644.42K | CN¥1,490,506.40K |
| Net Income | -CN¥151,368.12K | -CN¥5,710.67K | -CN¥4,707.33K | -CN¥5,784.52K | -CN¥7,127.37K | -CN¥7,277.77K |